Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

  title={Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures},
  author={Roger J. Porter and Arnaud Partiot and Rajesh C. Sachdeo and Virinder Nohria and Wayne M. Alves},
  pages={1197 - 1204}
Objective: To evaluate the efficacy and safety of retigabine 600, 900, and 1,200 mg/day administered three times daily as adjunctive therapy in patients with partial-onset seizures. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed. After an 8-week baseline phase, patients were randomized to a 16-week double-blind treatment period (8-week forced titration and 8-week maintenance) followed by either tapering or entry into an open-label extension study… 

Figures and Tables from this paper

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy

This study demonstrates that EZG(RTG) 1,200 mg/day is effective as add-on therapy for reducing seizure frequency in patients with drug-resistant partial-onset seizures.

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

In this dose-ranging, placebo-controlled trial, adjunctive EZG (RTG) was effective and generally well tolerated in adults with refractory partial-onset seizures.

Efficacy of Retigabine in Adjunctive Treatment of Partial Onset Seizures in Adults

  • M. Y. Splinter
  • Medicine, Biology
    Journal of central nervous system disease
  • 2013
Retigabine has been shown to have efficacy when used as adjunctive therapy in partial-onset seizures, and has less drug interactions than many other anticonvulsants because it is not metabolized through the P-450 system.

Adolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.

EZG/RTG PK appeared linear across the dosage range of 100 to 300 mg TID in adolescents with POS, and were consistent with adult observations, but the small sample size and short study duration preclude conclusions regarding the safety and efficacy of EZG /RTG.



Levetiracetam for partial seizures

Adjunctive therapy with levetiracetam was effective and well tolerated in controlling partial seizures and was higher than placebo during the entire evaluation period.

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures

Zonisamide is effective and well tolerated as an adjunctive agent for refractory partial-onset seizures and the minimal effective dosage was 100mg/d, but 400 mg/d was the most effective dosage.

New antiepileptic drugs: a systematic review of their efficacy and tolerability

Each drug was significantly better than placebo at preventing seizures, but none was significantly different from the others in terms of efficacy or tolerability, though the confidence intervals were wide Randomised trials comparing active treatments are needed to further evaluate these drugs.

Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects

The induction of LTG clearance due to retigabine was unexpected since RGB did not show enzyme induction in various other drug–drug interaction studies, and RGB and LTG exhibit a modest pharmacokinetic interaction on each other.

Metabolism of retigabine (D-23129), a novel anticonvulsant.

Plasma profiling and spectroscopic analysis of two isolated urinary metabolites obtained after single oral dosing of 600 mg retigabine in healthy volunteers indicated that both acetylation and glucuronidation are major metabolic pathways of retigABine in humans.

Statistical Aspects of the Measurement of Clinical Care in Epilepsy

Given such a rich variety of patterns for seizure recurrence it is not surprising that numerous measures have been employed both to portray the progression of epilepsy over time, and to summarise and assess the comparative usefulness of treatment.

On closed test procedures for dose‐response analysis

This paper concerns the testing of a dose-response effect in medical studies. We consider two situations. The first is when the drug effect on a parameter of interest is likely to increase (or